Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial
about
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes MellitusTeneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)Efficacy and safety of teneligliptin.Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
P2860
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 January 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of tenelig ...... ebo-controlled phase III trial
@en
Efficacy and safety of tenelig ...... bo-controlled phase III trial.
@nl
type
label
Efficacy and safety of tenelig ...... ebo-controlled phase III trial
@en
Efficacy and safety of tenelig ...... bo-controlled phase III trial.
@nl
prefLabel
Efficacy and safety of tenelig ...... ebo-controlled phase III trial
@en
Efficacy and safety of tenelig ...... bo-controlled phase III trial.
@nl
P2093
P2860
P921
P356
P1476
Efficacy and safety of tenelig ...... ebo-controlled phase III trial
@en
P2093
P2860
P304
P356
10.1111/DOM.12631
P577
2016-03-18T00:00:00Z